Apr 19 |
MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors
|
Apr 18 |
Enliven Therapeutics files to sell 6.43M shares for holders
|
Apr 11 |
Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program
|
Apr 11 |
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
|
Apr 9 |
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
|
Apr 9 |
Owning 36% shares,institutional owners seem interested in Enliven Therapeutics, Inc. (NASDAQ:ELVN),
|
Mar 28 |
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024
|
Mar 23 |
Enliven Therapeutics Inc Director Rahul Ballal Sells 13,278 Shares
|
Mar 19 |
Enliven Therapeutics announces $90M private placement to fund R&D activities
|
Mar 19 |
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
|